Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shijiazhuang Pharmaceutical Group Enters Oncology Drug Market With Acquisition

This article was originally published in PharmAsia News

Executive Summary

Shijiazhuang Pharmaceutical Group and Dalian Yuanda Pharmaceutical have signed a wide-ranging agreement under which Shijiazhuang Pharmaceutical Group will invest RMB 200 million, and both companies will jointly develop the local market for Yuanda's leading anti-tumor drug Elemene. The two firms will conduct clinical trials of Elemene emulsion injection in China and the U.S., and will also launch new drugs. Elemene injection is the only State FDA-approved drug for treating intracranial tumors, while Elemene emulsion injection is slated for U.S. clinical trials next year. Yuanda will become a subsidiary of SPG and undergo a name change to align with the group. SPG has identified anti-tumor drugs as one of its key development areas and the collaboration marks its entry into the anti-tumor patented drug market. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts